California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab ... or refraining from, any action on the basis of the content on ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ...